Viral Decay Dynamics in HIV‐Infected Patients Receiving Ritonavir‐Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV‐NAT 012) | Zendy

Mark Boyd | Zendy; Narendra M. Dixit | Zendy; Umaporn Siangphoe | Zendy; Neil Buss | Zendy; Miklos Salgo | Zendy; Joep M. A. Lange | Zendy; Praphan Phanuphak | Zendy; David A. Cooper | Zendy; Alan S. Perelson | Zendy; Kiat Ruxrungtham | Zendy

Open Access

Viral Decay Dynamics in HIV‐Infected Patients Receiving Ritonavir‐Boosted Saquinavir and Efavirenz With or Without Enfuvirtide: A Randomized, Controlled Trial (HIV‐NAT 012)

Author(s) -

Mark Boyd,

Narendra M. Dixit,

Umaporn Siangphoe,

Neil Buss,

Miklos Salgo,

Joep M. A. Lange,

Praphan Phanuphak,

David A. Cooper,

Alan S. Perelson,

Kiat Ruxrungtham

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/508291

Subject(s) - enfuvirtide , saquinavir , ritonavir , efavirenz , virology , protease inhibitor (pharmacology) , reverse transcriptase inhibitor , protease , reverse transcriptase , elvitegravir , darunavir , medicine , human immunodeficiency virus (hiv) , biology , viral load , antiretroviral therapy , immunology , gp41 , polymerase chain reaction , enzyme , genetics , biochemistry , antigen , gene , epitope

The availability of enfuvirtide enables assessment of whether human immunodeficiency virus (HIV) decay can be enhanced by targeting reverse transcriptase, protease, and fusion. We performed a 12-week study of 22 patients randomized to receive ritonavir-boosted saquinavir and efavirenz with (the 3-target arm) or without (the 2-target arm) enfuvirtide. We observed no difference in the mean+/-SD elimination-rate constant for overall decay (0.142+/-0.040 per day and 0.128 +/- 0.033 per day in the 2- and 3-target arms, respectively; P>.1) or for modeled first-phase decay rate (-0.62+/-0.34 per day and -0.51+/-0.16 per day; P>.1). Antiretroviral therapy that inhibits HIV reverse transcriptase and protease exerts potent antiviral effects that might not be augmented by the addition of an HIV fusion inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research